In addition, compared with the sh-TNFSF9 + DMSO group, the migration of pancreatic cancer cells in the sh-TNFSF9 + Wnt agonist group was significantly increased (P < 0.05) (Figure 4F, 4G). This evidence concerns the gene TNFSF9 and familial pancreatic carcinoma.